Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Systematic study of IgG4-autoimmune diseases to develop new treatment strategies

Project description

Exploring IgG4-autoimmune diseases for new treatment strategies

IgG4-autoimmune diseases (IgG4-AIDs) are rare but can seriously affect organs such as the skin, brain, nerves and kidneys. Many patients are unresponsive to current treatments. These diseases involve immune dysfunction and the production of harmful IgG4 antibodies that disrupt normal body functions. With the support of the Marie Skłodowska-Curie Actions programme, the IgG4-TREAT project will explore IgG4-AIDs by studying pathogenic IgG4 and the mechanisms of autoantibody production. It will create a humanised mouse model for testing a novel immune-apheresis therapy. The programme will combine university education with multidisciplinary training, preparing experts for careers in academia and industry, with a focus on digitalisation and sustainable research to tackle challenges such as climate change and social inequalities.

Objective

IgG4-autoimmune diseases (IgG4-AID) are rare but collectively correspond to a significant group of devastating diseases affecting
many different organs, e.g. skin, brain, nerves and kidney in patients that often remain unresponsive to current treatments. IgG4-AID
have commonalities indicating a shared underlying immunopathogenesis that make a joint approach to identify new therapeutic
targets and test new treatment strategies feasible and necessary. We hypothesize that genetic risk factors and a dysregulated
immune response may lead to an increased susceptibility to produce antibodies targeting self-proteins. These are of a special
subclass called IgG4, which are usually harmless but can cause disease in these patients by interfering with normal functions in the
body. We are the first consortium that aims to study IgG4-AID comparatively, including pathogenic IgG4, and the cells, molecules and
mechanisms involved in IgG4 autoantibody production, using an explorative multi-omics approaches in combination with state-ofthe-
art cell and molecular biology methodology. We will establish a new humanized mouse model of IgG4-AID for the development
and testing of a novel immune-apheresis based therapy aimed as immediate relief therapy for all IgG4-AID patients. Our innovative
training program combines university-based and multidisciplinary research-based training with state-of the art web-based training
and in-person trainings by the academic and non-academic sector. We aim to foster a new generation of experts in IgG4-AID that are
1) are highly employable both in the academic and industry sectors and qualified for innovative multidisciplinary translational
research with a focus on biomedical product development and 2) equipped with the skillsets for digitalization, awareness for gender
equality and diversity and competent in sustainable research and innovation approaches to address current and future challenges,
such as climate change, social inequalities and pandemics.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-DN-01

See all projects funded under this call

Coordinator

MEDIZINISCHE UNIVERSITAET WIEN
Net EU contribution
€ 540 662,40
Address
SPITALGASSE 23
1090 Wien
Austria
Region
Ostösterreich Wien Wien
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (8)

Partners (11)